{"id":"cd101","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion-related reactions"},{"rate":"null","effect":"Infections"},{"rate":"null","effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL4743205","moleculeType":"Unknown","molecularWeight":"1284.47"},"_fixedAt":"2026-03-30T12:04:41.068861","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD101 works by binding to beta-glucan, a polysaccharide component of the cell walls of fungi, thereby inhibiting the growth of fungal pathogens. This mechanism of action allows CD101 to selectively target and eliminate fungal infections, reducing the risk of invasive fungal disease.","oneSentence":"CD101 is a recombinant human monoclonal antibody targeting beta-glucan.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:49:58.289Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of invasive fungal disease"}]},"_fixedFields":["sideEffects","modality→Small Molecule"],"trialDetails":[{"nctId":"NCT02516904","phase":"PHASE1","title":"A Single Ascending Dose Study of CD101 IV in Healthy Subjects","status":"COMPLETED","sponsor":"Cidara Therapeutics Inc.","startDate":"2015-07","conditions":"Healthy","enrollment":32},{"nctId":"NCT03183661","phase":"","title":"A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial","status":"RECRUITING","sponsor":"Anterogen Co., Ltd.","startDate":"2016-11-16","conditions":"Crohn Disease","enrollment":9},{"nctId":"NCT02734862","phase":"PHASE2","title":"CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension","status":"COMPLETED","sponsor":"Cidara Therapeutics Inc.","startDate":"2016-07-26","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":207},{"nctId":"NCT02733432","phase":"PHASE2","title":"RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections","status":"COMPLETED","sponsor":"Cidara Therapeutics Inc.","startDate":"2016-06-08","conditions":"Candidiasis, Vulvovaginal, Mycoses, Yeast Infection","enrollment":126},{"nctId":"NCT02888197","phase":"","title":"Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization","status":"COMPLETED","sponsor":"Cidara Therapeutics Inc.","startDate":"2016-08-16","conditions":"Candidiasis, Vulvovaginal, Yeast Infection, Mycoses","enrollment":32},{"nctId":"NCT02551549","phase":"PHASE1","title":"An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects","status":"COMPLETED","sponsor":"Cidara Therapeutics Inc.","startDate":"2015-09","conditions":"Healthy","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":166,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CD101 for Injection"],"phase":"phase_2","status":"active","brandName":"CD101","genericName":"CD101","companyName":"Cidara Therapeutics Inc.","companyId":"cidara-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CD101 is a recombinant human monoclonal antibody targeting beta-glucan. Used for Treatment of invasive fungal disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}